Literature DB >> 16096401

Clinical relevance of occult tumor cells in lymph nodes from gastric cancer patients.

Fania S Doekhie1, Wilma E Mesker, J Han J M van Krieken, Niels F M Kok, Henk H Hartgrink, Elma Klein Kranenbarg, Hein Putter, Peter J K Kuppen, Hans J Tanke, Rob A E M Tollenaar, Cornelis J H van de Velde.   

Abstract

The current method for staging in gastric cancer is not sufficient as even after a complete primary tumor resection, patients with node-negative gastric cancer suffer from disease recurrence. In this study, the relation between disease recurrence and the presence of occult tumor cells (OTC) in lymph nodes from gastric cancer patients was evaluated. In a case-control design, lymph nodes from 40 cases (disease recurrence) and 41 controls (no disease recurrence and followed for at least five years) with gastric cancer were examined for the presence of OTC, that comprised micrometastases (MM; >0.2 mm and < or =2.0 mm) and isolated tumor cells (ITC; < or =0.2 mm). The original hematoxylin and eosin-stained sections of all lymph nodes from cases and controls were previously considered as tumor-negative by the local pathologist. Fresh hematoxylin and eosin-stained sections were screened by conventional microscopy. Histologic sections stained by immunohistochemistry with anticytokeratin antibodies CAM5.2 were screened by conventional and automated microscopy. Tumor cells were detected in lymph nodes from 40 of 81 (49%) patients. There was no significant difference in the presence of OTC, MM, or ITC between the case and control groups (P = 0.658, P = 0.691, P = 0.887, respectively). However, significantly more cases presented with 20% or more OTC-positive lymph nodes (P = 0.015). A multivariate logistic regression analysis showed that examination of less than five lymph nodes (odds ratio, 13.8; 95% confidence interval, 1.6-120.6, P = 0.018) was the only significant independent risk factor for disease recurrence, especially for locoregional disease recurrence (odds ratio, 20.4; 95% confidence interval, 2.2-190.8, P = 0.008). A similar analysis for distant disease recurrence showed a percentage of 20% or more OTC-positive lymph nodes to be the only significant independent risk factor (odds ratio, 15.6, 95% confidence interval, 1.6-151.4, P = 0.018). The sensitivity of immunohistochemistry evaluated by microscopy to identify cases with 20% or more OTC-positive lymph nodes increased from 8% for conventional microscopy to 22% for automated microscopy (McNemar's test, P = 0.063). The mere presence of OTC-positive lymph nodes in gastric cancer patients did not predict disease recurrence. However, the number of examined lymph nodes and the percentage of OTC-positive lymph nodes were independent risk factors for locoregional disease recurrence and distant disease recurrence, respectively. Automated microscopy was essential in identifying patients with 20% or more OTC-positive lymph nodes. Therefore, a maximum number of lymph nodes should be removed and meticulously examined for OTC to identify high-risk patients. These patients should be considered for additional treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16096401     DOI: 10.1097/01.pas.0000160439.38770.cb

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  16 in total

1.  Lymph node, peritoneal and bone marrow micrometastases in gastric cancer: Their clinical significance.

Authors:  John Griniatsos; Othon Michail; Nikoletta Dimitriou; Ioannis Karavokyros
Journal:  World J Gastrointest Oncol       Date:  2012-02-15

Review 2.  [Minimal residual tumor in gastrointestinal carcinoma. Relevance to prognosis and oncologic surgical consequences].

Authors:  S Gretschel; A Bembenek; T Schulze; W Kemmner; P M Schlag
Journal:  Chirurg       Date:  2006-12       Impact factor: 0.955

3.  Occult Tumour Cells in Lymph Nodes from Gastric Cancer Patients: Should Isolated Tumour Cells Also Be Considered?

Authors:  A Tavares; X Wen; J Maciel; F Carneiro; M Dinis-Ribeiro
Journal:  Ann Surg Oncol       Date:  2020-05-04       Impact factor: 5.344

Review 4.  N staging: the role of the pathologist.

Authors:  Costanza De Marco; Alberto Biondi; Riccardo Ricci
Journal:  Transl Gastroenterol Hepatol       Date:  2017-02-20

5.  Gastric cancer lymph node resection-the more the merrier?

Authors:  Henrik Nienhüser; Thomas Schmidt
Journal:  Transl Gastroenterol Hepatol       Date:  2018-01-05

Review 6.  Methylation-mediated gene silencing as biomarkers of gastric cancer: a review.

Authors:  Jun Nakamura; Tomokazu Tanaka; Yoshihiko Kitajima; Hirokazu Noshiro; Kohji Miyazaki
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

7.  Skip lymph node metastasis in gastric cancer: is it skipping or skipped?

Authors:  Yoon Young Choi; Ji Yeong An; Ali Guner; Dae Ryong Kang; In Cho; In Gyu Kwon; Hyun Beak Shin; Woo Jin Hyung; Sung Hoon Noh
Journal:  Gastric Cancer       Date:  2015-02-24       Impact factor: 7.370

8.  Gastric carcinoma: stage migration by immunohistochemically detected lymph node micrometastases.

Authors:  Theresa L A Jeuck; Christian Wittekind
Journal:  Gastric Cancer       Date:  2014-02-19       Impact factor: 7.370

9.  Clinical impact of different detection methods for disseminated tumor cells in bone marrow of patients undergoing surgical resection of colorectal liver metastases: a prospective follow-up study.

Authors:  F Jeroen Vogelaar; Wilma E Mesker; Arjen M Rijken; Gaby W van Pelt; Antonia M van Leeuwen; Hans J Tanke; Rob A Tollenaar; Gerrit J Liefers
Journal:  BMC Cancer       Date:  2010-04-20       Impact factor: 4.430

10.  Routine modified D2 lymphadenectomy performance in pT1-T2N0 gastric cancer.

Authors:  John Griniatsos; Hara Gakiopoulou; Eugenia Yiannakopoulou; Nikoletta Dimitriou; Gerasimos Douridas; Afrodite Nonni; Theodoros Liakakos; Evangelos Felekouras
Journal:  World J Gastroenterol       Date:  2009-11-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.